Evolent Health (EVH) and Its Peers Critical Review
Evolent Health (NYSE: EVH) is one of 18 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it contrast to its competitors? We will compare Evolent Health to related companies based on the strength of its earnings, dividends, institutional ownership, analyst recommendations, valuation, profitability and risk.
This is a summary of recent recommendations for Evolent Health and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Evolent Health Competitors||70||391||762||10||2.58|
Evolent Health presently has a consensus price target of $28.36, suggesting a potential upside of 56.27%. As a group, “Medical Software & Technology Services” companies have a potential upside of 17.84%. Given Evolent Health’s stronger consensus rating and higher possible upside, equities analysts clearly believe Evolent Health is more favorable than its competitors.
Earnings & Valuation
This table compares Evolent Health and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Evolent Health||$361.53 million||-$51.15 million||-15.00|
|Evolent Health Competitors||$376.98 million||$34.79 million||8.35|
Evolent Health’s competitors have higher revenue and earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
82.5% of Evolent Health shares are owned by institutional investors. Comparatively, 63.1% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 8.8% of Evolent Health shares are owned by insiders. Comparatively, 24.4% of shares of all “Medical Software & Technology Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Evolent Health and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Evolent Health Competitors||-18.12%||-11.70%||-2.05%|
Risk & Volatility
Evolent Health has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Evolent Health’s competitors have a beta of 1.33, suggesting that their average stock price is 33% more volatile than the S&P 500.
Evolent Health beats its competitors on 7 of the 11 factors compared.
About Evolent Health
Evolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company’s services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company’s technology platform that aggregates and analyzes data, manages care workflows and engages patients.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.